Calcipotriol - MC2 Therapeutics

Drug Profile

Calcipotriol - MC2 Therapeutics

Alternative Names: Calcipotriene MC2-16 PAD™ Cream; MC2-01 (calcipotriol); MC2-04; MC2-16; PADcalci

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Drug Delivery Solutions ApS
  • Developer Drug Delivery Solutions ApS; MC2 Therapeutics
  • Class Antipsoriatics; Cyclohexanes; Dihydroxycholecalciferols; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Plaque psoriasis
  • Discontinued Psoriasis

Most Recent Events

  • 03 Apr 2017 Discontinued - Phase-II for Plaque psoriasis of MC2-01 calcipotriol in Germany (Topical, Ointment), because not listed on MC2 Therapeutics pipeline, April 2017
  • 03 Apr 2017 Preclinical trials of MC2-16 calcipotriol in Plaque psoriasis in Denmark (Topical, Cream) (MC2 Therapeutics pipeline, April 2017)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top